Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

The ITCC-P4 PDX Platform Enables Preclinical Testing of Pediatric Cancers.

Cancer research·2026

Same author

Talazoparib engages innate immune activation via PARP trapping-dependent cGAS/STING activation in Ewing Sarcoma.

Cancer letters·2026

Same author

Corrigendum to "Management of atypical cartilaginous tumors (ACT): An Italian Sarcoma Group (ISG) consensus document" [Crit. Rev. Oncol. Hematol. 223 (2026) 105358].

Critical reviews in oncology/hematology·2026

Same author

Molecular tumor board availability and organization in sarcoma referral centers in Italy: are we on the right track?

Frontiers in oncology·2026

Same author

ZEB1 integrates stemness, differentiation blockade and immune suppression to orchestrate osteosarcoma aggressiveness.

Journal of experimental & clinical cancer research : CR·2026

Same author

Mevalonate pathway activation in Ewing sarcoma reveals a 3D-specific synergy between statins and BCL-xL inhibition.

Molecular therapy. Oncology·2026

Search research articles

Related Experiment Video

Updated: Nov 25, 2025

Author Spotlight: Replicating Human Osteosarcoma Progression in Immunodeficient Mice for Cancer Study

Author Spotlight: Replicating Human Osteosarcoma Progression in Immunodeficient Mice for Cancer Study

Published on: March 22, 2024

Ewing Sarcoma PDX Models.

Didier Surdez¹, Lorena Landuzzi², Katia Scotlandi²

¹INSERM U830, Équipe Labellisée LNCC, Genetics and Biology of Pediatric Cancers, PSL Research University, SIREDO Oncology Centre, Institut Curie Research Centre, Paris, France.

Methods in Molecular Biology (Clifton, N.J.)

|December 16, 2020

Summary

Patient-derived xenografts (PDXs) offer a promising avenue for studying rare pediatric tumors like Ewing sarcoma (EWS). These models better reflect human tumor characteristics, aiding in preclinical research and treatment development.

Keywords:

Ewing sarcoma Immunodeficient mice Patient-derived xenografts Pediatric tumors Preclinical models

More Related Videos

The In ovo CAM-assay as a Xenograft Model for Sarcoma

The In ovo CAM-assay as a Xenograft Model for Sarcoma

Published on: July 17, 2013

Utilization of Ultrasound Guided Tissue-directed Cellular Implantation for the Establishment of Biologically Relevant Metastatic Tumor Xenografts

Utilization of Ultrasound Guided Tissue-directed Cellular Implantation for the Establishment of Biologically Relevant Metastatic Tumor Xenografts

Published on: May 25, 2018

Related Experiment Videos

Last Updated: Nov 25, 2025

Author Spotlight: Replicating Human Osteosarcoma Progression in Immunodeficient Mice for Cancer Study

Author Spotlight: Replicating Human Osteosarcoma Progression in Immunodeficient Mice for Cancer Study

Published on: March 22, 2024

The In ovo CAM-assay as a Xenograft Model for Sarcoma

The In ovo CAM-assay as a Xenograft Model for Sarcoma

Published on: July 17, 2013

Utilization of Ultrasound Guided Tissue-directed Cellular Implantation for the Establishment of Biologically Relevant Metastatic Tumor Xenografts

Utilization of Ultrasound Guided Tissue-directed Cellular Implantation for the Establishment of Biologically Relevant Metastatic Tumor Xenografts

Published on: May 25, 2018

Area of Science:

Oncology
Pediatric Medicine
Translational Research

Background:

Ewing sarcoma (EWS) is a rare pediatric malignancy with limited available preclinical models.
Current models, such as cell-derived xenografts (CDX), may not fully recapitulate tumor complexity.
Patient-derived xenografts (PDXs) are increasingly recognized for their potential to bridge this gap.

Purpose of the Study:

To describe a comprehensive method for generating Ewing sarcoma (EWS) patient-derived xenograft (PDX) models.
To detail the validation and molecular characterization processes for these EWS PDX models.
To enhance the availability of reliable preclinical models for EWS research.

Main Methods:

Detailed protocol for establishing EWS PDX models from patient tumor samples.
Methodologies for validating PDX model fidelity to the original tumor.
Techniques for comprehensive molecular characterization of established PDX models.

Main Results:

Successful generation of EWS PDX models is demonstrated.
Validation confirms the recapitulation of key tumor features in PDX models.
Molecular characterization provides a detailed profile of the generated models.

Conclusions:

Ewing sarcoma PDX models represent valuable tools for preclinical research.
These models offer improved fidelity to the original tumor microenvironment and heterogeneity.
The described methods facilitate the development and characterization of robust EWS PDX models for future studies.